Stock Events

Stock Events

Sagimet Biosciences 

$10.92
66
-$0.07-0.64% Thursday 20:00
+$0.03+0.27%Thursday 23:30After hours

Statistics

Day High
10.93
Day Low
10.9
52W High
11.24
52W Low
4.5
Volume
52,631
Avg. Volume
-
Mkt Cap
678.77M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.67
-0.53
-0.39
-0.25
Expected EPS
-0.25536
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-51.04MNet Income

Analyst Ratings

34.75Average Price Target
The highest estimate is 56.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SGMT. It's not an investment recommendation.
Amazon
11
AMZN
NVIDIA
11
NVDA
Microsoft
10
MSFT
Apple
9
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Viking Therapeutics
VKTX
Mkt Cap3.75B
Viking Therapeutics is developing therapies for metabolic and endocrine disorders, similar to Sagimet's focus on NASH (non-alcoholic steatohepatitis).
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.33B
Madrigal Pharmaceuticals focuses on the development of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, directly competing in the NASH space.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.34M
Galmed Pharmaceuticals is engaged in the development of oral therapies for the treatment of liver diseases, including NASH, positioning it as a competitor.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its broader portfolio, includes treatments for liver diseases such as NASH, competing with Sagimet's focus areas.
Agios Pharmaceuticals
AGIO
Mkt Cap1.99B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, including metabolic disorders, which puts it in competition with Sagimet's metabolic disease focus.

About

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Show more...
CEO
David Happel
Employees
16
Country
United States
ISIN
US7867001049
WKN
000A3CPAM

Listings

MU
DE
0O2.MU
STU
DE
0O2.STU
F
DE
0O2.F
XNAS
US
SGMT

0 Comments

Share your thoughts

FAQ

What is Sagimet Biosciences stock price today?▼
The current price of SGMT is $10.92 USD — it has decreased by -0.64% in the past 24 hours. Watch Sagimet Biosciences stock price performance more closely on the chart.
What is Sagimet Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Sagimet Biosciences stocks are traded under the ticker SGMT.
Is Sagimet Biosciences stock price growing?▼
SGMT stock has risen by +3.51% compared to the previous week, the month change is a +36.67% rise, over the last year Sagimet Biosciences has showed a +50.62% increase.
What is Sagimet Biosciences market cap?▼
Today Sagimet Biosciences has the market capitalization of 678.77M
When is the next Sagimet Biosciences earnings date?▼
Sagimet Biosciences is going to release the next earnings report on November 12, 2026.
What were Sagimet Biosciences earnings last quarter?▼
SGMT earnings for the last quarter are -0.26 USD per share, whereas the estimation was -0.25 USD resulting in a -3.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Sagimet Biosciences revenue for the last year?▼
Sagimet Biosciences revenue for the last year amounts to 0 USD.
What is Sagimet Biosciences net income for the last year?▼
SGMT net income for the last year is -51.04M USD.
How many employees does Sagimet Biosciences have?▼
As of September 04, 2026, the company has 16 employees.
In which sector is Sagimet Biosciences located?▼
Sagimet Biosciences operates in the Health & Wellness sector.
When did Sagimet Biosciences complete a stock split?▼
Sagimet Biosciences has not had any recent stock splits.
Where is Sagimet Biosciences headquartered?▼
Sagimet Biosciences is headquartered in FOSTER CITY, United States.